- Home
- MKZR vs DYAI Comparison
MKZR vs DYAI Comparison
Compare MKZR & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- DYAI
- Stock Information
- Founded
- MKZR 2012
- DYAI 1979
- Country
- MKZR United States
- DYAI United States
- Employees
- MKZR N/A
- DYAI N/A
- Industry
- MKZR
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MKZR
- DYAI Health Care
- Exchange
- MKZR Nasdaq
- DYAI Nasdaq
- Market Cap
- MKZR 56.6M
- DYAI 54.4M
- IPO Year
- MKZR N/A
- DYAI 2004
- Fundamental
- Price
- MKZR $2.41
- DYAI $1.50
- Analyst Decision
- MKZR
- DYAI Strong Buy
- Analyst Count
- MKZR 0
- DYAI 1
- Target Price
- MKZR N/A
- DYAI $6.00
- AVG Volume (30 Days)
- MKZR 97.8K
- DYAI 213.3K
- Earning Date
- MKZR 01-01-0001
- DYAI 11-12-2024
- Dividend Yield
- MKZR 7.26%
- DYAI N/A
- EPS Growth
- MKZR N/A
- DYAI N/A
- EPS
- MKZR N/A
- DYAI N/A
- Revenue
- MKZR $17,563,335.00
- DYAI $3,364,548.00
- Revenue This Year
- MKZR N/A
- DYAI $51.30
- Revenue Next Year
- MKZR N/A
- DYAI $73.26
- P/E Ratio
- MKZR N/A
- DYAI N/A
- Revenue Growth
- MKZR N/A
- DYAI 13.82
- 52 Week Low
- MKZR $1.05
- DYAI $0.93
- 52 Week High
- MKZR $5.50
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- DYAI 42.12
- Support Level
- MKZR N/A
- DYAI $1.45
- Resistance Level
- MKZR N/A
- DYAI $1.79
- Average True Range (ATR)
- MKZR 0.00
- DYAI 0.24
- MACD
- MKZR 0.00
- DYAI -0.05
- Stochastic Oscillator
- MKZR 0.00
- DYAI 7.25
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.